Fresenius Delayed By FDA Inspection Uncertainty As It Works Towards US Pegfilgrastim Launch
Biosimilars Head Ali Ahmed Talks About Company’s Biosimilars Strategy
Executive Summary
Ali Ahmed, senior vice president of biosimilars at Fresenius Kabi, considers the launch of the firm’s proposed Neulasta (pegfilgrastim) biosimilar in the US “an important milestone for the company.” However, he explains in an exclusive interview with Generics Bulletin, delays to necessary FDA inspections are creating uncertainty for the firm over launch timing.
You may also be interested in...
Fresenius Kabi Introduces Cancer Copay Scheme For Generics
German pharma giant Fresenius Kabi has introduced a copay scheme for a number of its generic oncology medicines in the US, which could completely eliminate monthly costs for certain patients.
Are Investors ‘Skeptical’ Of Fresenius Kabi’s €495m mAbxience Acquisition?
Fresenius Kabi’s proposed agreement to acquire a majority 55% stake in biosimilars firm mAbxience has been put under the microscope by one analyst, amid setbacks that have stymied the return on investment for Kabi’s nascent biosimilars unit.
Kabi Brings In Reddy’s Rituximab As Biosimilar Breakeven Date Retreats
The Fresenius group had much to say of Fresenius Kabi’s biosimilar business during the firm’s Q4 and year-end results call, which disclosed a US in-licensing deal for Dr Reddy’s proposed rituximab biosimilar and suggested additional biosimilar manufacturing is among its top priorities.